Activating Compound | Comment | Organism | Structure |
---|---|---|---|
BLX-1002 | has no affinity to peroxisome proliferator-activated receptors (PPAR), stimulation of beta-cells with BLX-1002 induces activation of AMPK at high glucose. BLX-1002 selectively potentiates insulin secretion induced by high glucose in normal and diabetic islets in a PI3K-dependent manner. This effect is associated with an increased cytoplasmic free Ca2+ concentration mediated through Ca2+ mobilization, and an enhanced activation of AMPK | Mus musculus | |
BLX-1015 | 0.01 mM significantly enhances AMPK phosphorylation, to an extent similar to that of BLX-1002. Potentiates pioglitazone-, but not fenofibrate-induced insulin secretion | Mus musculus | |
metformin | stimulates AMPK, does not induce any significant change in glucose-stimulated insulin secretion | Mus musculus |
Application | Comment | Organism |
---|---|---|
drug development | the glucose-sensitive stimulatory impact of BLX-1002 on beta-cell function associated with AMPK activation may translate into substantial clinical benefits of the drug in the management of type 2 diabetes, by avoidance of hypoglycemia | Mus musculus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
6-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimidine | compound C, at a concentration of 0.02 mM, suppresses the glucose-stimulated rise in cytoplasmic free Ca2+ concentration by 75%, and the cytoplasmic free Ca2+ concentration response to BLX-1002 is also significantly suppressed | Mus musculus | |
glucose | AMPK activity is inhibited by high glucose | Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
pancreatic beta cell | - |
Mus musculus | - |
pancreatic islet | - |
Mus musculus | - |
Synonyms | Comment | Organism |
---|---|---|
AMP-activated protein kinase | - |
Mus musculus |
AMPK | - |
Mus musculus |